praziquantel
Phase 3Completed 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Schistosomiasis
Conditions
Schistosomiasis
Trial Timeline
Aug 1, 2008 → Sep 1, 2012
NCT ID
NCT01558336About praziquantel
praziquantel is a phase 3 stage product being developed by Hikma Pharmaceuticals for Schistosomiasis. The current trial status is completed. This product is registered under clinical trial identifier NCT01558336. Target conditions include Schistosomiasis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01558336 | Phase 3 | Completed |
Competing Products
3 competing products in Schistosomiasis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Praziquantel 600Mg Oral Tablet x 5 + Praziquantel 600Mg Oral Tablet x 1 | Merck | Phase 2/3 | 65 |
| Biltricide (racemate praziquantel) oral tablets + Racemate Praziquantel ODT + Levo Praziquantel ODT | Merck | Phase 2 | 52 |
| L-PZQ ODT 50 mg/kg + Biltricide® + L-PZQ ODT 60 mg/kg | Merck | Phase 3 | 77 |